JP2010510223A5 - - Google Patents

Download PDF

Info

Publication number
JP2010510223A5
JP2010510223A5 JP2009537223A JP2009537223A JP2010510223A5 JP 2010510223 A5 JP2010510223 A5 JP 2010510223A5 JP 2009537223 A JP2009537223 A JP 2009537223A JP 2009537223 A JP2009537223 A JP 2009537223A JP 2010510223 A5 JP2010510223 A5 JP 2010510223A5
Authority
JP
Japan
Prior art keywords
agent
tim
antigen
activity
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009537223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010510223A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/024067 external-priority patent/WO2008060617A2/en
Publication of JP2010510223A publication Critical patent/JP2010510223A/ja
Publication of JP2010510223A5 publication Critical patent/JP2010510223A5/ja
Withdrawn legal-status Critical Current

Links

JP2009537223A 2006-11-15 2007-11-15 Tim−3調節物質の治療的使用 Withdrawn JP2010510223A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85939106P 2006-11-15 2006-11-15
US92394507P 2007-04-17 2007-04-17
PCT/US2007/024067 WO2008060617A2 (en) 2006-11-15 2007-11-15 Therapeutic uses of tim-3 modulators

Publications (2)

Publication Number Publication Date
JP2010510223A JP2010510223A (ja) 2010-04-02
JP2010510223A5 true JP2010510223A5 (cg-RX-API-DMAC7.html) 2012-01-26

Family

ID=39402274

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009537223A Withdrawn JP2010510223A (ja) 2006-11-15 2007-11-15 Tim−3調節物質の治療的使用

Country Status (6)

Country Link
US (1) US20100061992A1 (cg-RX-API-DMAC7.html)
EP (1) EP2081961A2 (cg-RX-API-DMAC7.html)
JP (1) JP2010510223A (cg-RX-API-DMAC7.html)
AU (1) AU2007319806A1 (cg-RX-API-DMAC7.html)
CA (1) CA2668693A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008060617A2 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010084999A1 (en) * 2009-01-26 2010-07-29 Protegene, Inc. Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases
US8883174B2 (en) * 2009-03-25 2014-11-11 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
TR201807750T4 (tr) * 2010-06-11 2018-06-21 Kyowa Hakko Kirin Co Ltd Anti-TIM-3 antikoru.
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
US10513540B2 (en) 2012-07-31 2019-12-24 The Brigham And Women's Hospital, Inc. Modulation of the immune response
US20140120157A1 (en) * 2012-09-19 2014-05-01 Georgetown University Targeted liposomes
EP3679950A1 (en) 2012-10-12 2020-07-15 The Brigham and Women's Hospital, Inc. Enhancement of the immune response
PL2911676T3 (pl) 2012-10-29 2020-12-28 The Board Of Trustees Of The University Of Arkansas Nowe adiuwanty śluzówkowe oraz systemy dostarczania
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
BR112016020919A2 (pt) 2014-03-12 2018-01-23 Yeda Res & Dev redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
UY36032A (es) 2014-03-14 2015-10-30 Novartis Ag Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
RS61678B1 (sr) 2014-05-28 2021-05-31 Agenus Inc Anti-gitr antitela i postupci za njihovu primenu
CN107206071A (zh) 2014-09-13 2017-09-26 诺华股份有限公司 Alk抑制剂的联合疗法
US20180298095A1 (en) * 2015-04-24 2018-10-18 The Brigham And Women's Hospital, Inc. Interactions between ceacam and tim family members
WO2016179194A1 (en) * 2015-05-04 2016-11-10 Jounce Therapeutics, Inc. Lilra3 and method of using the same
US10682390B2 (en) 2015-07-16 2020-06-16 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods of use thereof
AU2017228365B2 (en) * 2016-03-04 2021-05-27 Galectin Sciences, Llc Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof
FR3051192B1 (fr) * 2016-05-13 2020-12-25 Univ De Lorraine Methode de purification de proteines recombinantes par affinite basee sur l'activite lectinique du domaine crd d'une galectine
NZ749355A (en) 2016-05-27 2023-04-28 Agenus Inc Anti-tim-3 antibodies and methods of use thereof
EP4512829A3 (en) 2016-07-14 2025-06-11 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
BR112019023722A2 (pt) 2017-05-12 2020-05-26 Galectin Sciences, Llc Compostos para a prevenção e tratamento de doenças e o uso dos mesmos
CN111201030B (zh) * 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CA3127113A1 (en) 2019-01-30 2020-08-06 Dongxu Sun Anti-gal3 antibodies and uses thereof
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
KR102536302B1 (ko) * 2020-02-25 2023-05-26 국립암센터 Tim-3 에 특이적으로 결합하는 단일클론항체 및 이의 용도
JP2023528797A (ja) 2020-05-26 2023-07-06 トゥルーバインディング,インコーポレイテッド ガレクチン-3を遮断することにより炎症性疾患を処置する方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003063792A2 (en) * 2002-01-30 2003-08-07 The Brigham And Women's Hospital, Inc. Compositions and methods related to tim-3, a th1-specific cell surface molecule
EP1685159B1 (en) * 2003-10-03 2012-08-01 Brigham & Women's Hospital Tim-3 polypeptides

Similar Documents

Publication Publication Date Title
JP2010510223A5 (cg-RX-API-DMAC7.html)
Monnet et al. Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study
JP7215997B2 (ja) 前立腺特異的膜抗原(psma)を標的とする三重特異性タンパク質と使用方法
Samy et al. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases
US10392444B2 (en) Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
Eriksson et al. Expression of interleukin 1α and β, and interleukin 1 receptor antagonist mRNA in the rat central nervous system after peripheral administration of lipopolysaccharides
US20130142755A1 (en) Methods for Improving Immune Function and Methods for Prevention or Treatment of Disease in a Mammalian Subject
Cook et al. Granulocyte macrophage colony-stimulating factor receptor α expression and its targeting in antigen-induced arthritis and inflammation
Xiao et al. The IL-2/Anti-IL-2 complex attenuates cardiac ischaemia-reperfusion injury through expansion of regulatory T cells
JP2004501631A5 (cg-RX-API-DMAC7.html)
Weber et al. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF‐3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma
AU2010248935B2 (en) Methods and compositions for treating lupus
US20030007972A1 (en) Cytokine antagonists and other biologics for the treatment of bone metastases
JP2006523682A5 (cg-RX-API-DMAC7.html)
JP2011507891A5 (cg-RX-API-DMAC7.html)
JP2002537362A (ja) ビオチン化ケモカイン抗体複合体
JP2024028454A (ja) 糖尿病、肝炎、および/または炎症性肝疾患を治療するための方法
EP3880710A2 (en) B-cell activating cd73 antibodies
WO2020190977A1 (en) Treatment of cancers using sephb4-hsa fusion proteins
CN108350069A (zh) 针对il-23的多肽
Rongioletti et al. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab
Lampson Beyond inflammation: site-directed immunotherapy
KR20200068746A (ko) Il8의 emt 경로 차단 및 암 줄기 세포 극복(il8 bloking emt pathway and overcoming cancer stem cells)
Koschella et al. CD40 ligation in vivo induces bystander proliferation of memory phenotype CD8 T cells
Arnason Tumour necrosis factor neutralization in MS: a cautionary tale